European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemc

- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment -LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authoriza...

Related Keywords

Rome ,Lazio ,Italy ,France ,Boston ,Massachusetts ,United States ,London ,City Of ,United Kingdom ,Australia ,America ,Franco Locatelli ,Heather Nichols ,Reshma Kewalramani ,Companies To Work ,Vertex Pharmaceuticals Incorporated Nasdaq ,Youtube ,Exchange Commission ,Catholic University Of The Sacred Heart ,Linkedin ,European Commission ,Department Of Pediatric Hematology ,Vertex Pharmaceuticals Incorporated ,European Union ,Chief Executive Officer ,Catholic University ,Sacred Heart ,Pediatric Hematology ,Bambino Ges ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Conditional Marketing Authorizations ,North America ,Latin America ,Top Employers ,Private Securities Litigation Reform Act ,